Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Media
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsShortsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Radiation Oncology|
Surgery
Advertisement

Kenny K. L. Yeo

Advertisement

Articles by Kenny K. L. Yeo

4 Bacopaside: Exploring Its Potential in Addressing Chemoresistance and Modulating Doxorubicin Accumulation in Triple-Negative Breast Cancer Cells

4 Bacopaside: Exploring Its Potential in Addressing Chemoresistance and Modulating Doxorubicin Accumulation in Triple-Negative Breast Cancer Cells

BySima K. Rad,Kenny K. L. Yeo,Runhao Li,Saifei Liu,Fangmeinuo Wu,Kevin A. Fenix,Timothy J. Price,Wendy Ingman,Amanda R. Townsend,Eric Smith
August 29th 2024
Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on CancerNetwork

    1

    Durvalumab Plus BCG Earns FDA Approval For High-Risk NMIBC

    2

    ASCO 2026: The Presentations That May Shape The Future of Multiple Myeloma

    3

    How the Landscape of GI Oncology is Evolving: A 2026 ASCO Preview

    4

    Prescribing Exercise in Oncology: Moving Beyond “Good Luck”

    5

    85 rwpCR and rwEFS in Early-Stage Triple-Negative Breast Cancer Patients From Community Oncology Are Concordant With Trial End Point Estimates

    • About
    • Advertise
    • CureToday.com
    • OncLive.com
    • OncNursingNews.com
    • TargetedOnc.com
    • Editorial
    • Contact
    • Terms and Conditions
    • Privacy
    • Do Not Sell My Personal Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us